Keymed Biosciences Inc 02162
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 897
- Website
- https://www.keymedbio.com
Comparables
Valuation
|
Metric
|
02162
|
02257
|
02171
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 2.65 | 1.87 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
02162
|
02257
|
02171
|
|---|---|---|---|
Quick Ratio | 8.82 | 3.44 | 9.49 |
Current Ratio | 9.36 | 4.51 | 9.55 |
Interest Coverage | −24.76 | −86.17 | −174.85 |
Quick Ratio
02162
02257
02171
Profitability
|
Metric
|
02162
|
02257
|
02171
|
|---|---|---|---|
Return on Assets (Normalized) | −8.02% | −60.85% | −28.70% |
Return on Equity (Normalized) | −10.29% | −108.56% | −35.29% |
Return on Invested Capital (Normalized) | −11.03% | −94.28% | −35.38% |
Return on Assets
02162
02257
02171
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Myqxhpgvfr | Jqlpc | $635.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lmybfwrq | Fmtrk | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nsjmxmkvv | Xbznc | $114.2 Bil | |||
| Moderna Inc
MRNA
| Yccdtjdfn | Cdhby | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Flwfgrpb | Ljvj | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Hrrtrcm | Zjnp | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cyxqmlrtv | Wcztnm | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rzykvcww | Nbxzbf | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Vykzxwr | Pjcw | $12.8 Bil | |||
| Incyte Corp
INCY
| Jbpkvtzq | Kbxxwx | $12.2 Bil |